U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07330674) titled 'A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses' on Nov. 14, 2025.
Brief Summary: This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Age Related Macular Degeneration (ARMD)
AMD - Age-Related Macular Degeneration
Intervention:
DRUG: ABF-101
orally, QD
DRUG: Placebo
orally, QD
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Aptabio Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Dai...